• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算肾小球滤过率和蛋白尿与同期实验室异常的关系:全球联盟的个体参与者数据荟萃分析。

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.

机构信息

Division of Nephrology, Tufts Medical Center, Boston, MA.

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

出版信息

Am J Kidney Dis. 2019 Feb;73(2):206-217. doi: 10.1053/j.ajkd.2018.08.013. Epub 2018 Oct 19.

DOI:10.1053/j.ajkd.2018.08.013
PMID:30348535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6348050/
Abstract

RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) is complicated by abnormalities that reflect disruption in filtration, tubular, and endocrine functions of the kidney. Our aim was to explore the relationship of specific laboratory result abnormalities and hypertension with the estimated glomerular filtration rate (eGFR) and albuminuria CKD staging framework.

STUDY DESIGN

Cross-sectional individual participant-level analyses in a global consortium.

SETTING & STUDY POPULATIONS: 17 CKD and 38 general population and high-risk cohorts.

SELECTION CRITERIA FOR STUDIES

Cohorts in the CKD Prognosis Consortium with data for eGFR and albuminuria, as well as a measurement of hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, or calcium, or hypertension.

DATA EXTRACTION

Data were obtained and analyzed between July 2015 and January 2018.

ANALYTICAL APPROACH

We modeled the association of eGFR and albuminuria with hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, and calcium values using linear regression and with hypertension and categorical definitions of each abnormality using logistic regression. Results were pooled using random-effects meta-analyses.

RESULTS

The CKD cohorts (n=254,666 participants) were 27% women and 10% black, with a mean age of 69 (SD, 12) years. The general population/high-risk cohorts (n=1,758,334) were 50% women and 2% black, with a mean age of 50 (16) years. There was a strong graded association between lower eGFR and all laboratory result abnormalities (ORs ranging from 3.27 [95% CI, 2.68-3.97] to 8.91 [95% CI, 7.22-10.99] comparing eGFRs of 15 to 29 with eGFRs of 45 to 59mL/min/1.73m), whereas albuminuria had equivocal or weak associations with abnormalities (ORs ranging from 0.77 [95% CI, 0.60-0.99] to 1.92 [95% CI, 1.65-2.24] comparing urinary albumin-creatinine ratio > 300 vs < 30mg/g).

LIMITATIONS

Variations in study era, health care delivery system, typical diet, and laboratory assays.

CONCLUSIONS

Lower eGFR was strongly associated with higher odds of multiple laboratory result abnormalities. Knowledge of risk associations might help guide management in the heterogeneous group of patients with CKD.

摘要

背景与目的

慢性肾脏病(CKD)的并发症反映了肾脏滤过、肾小管和内分泌功能的紊乱。我们旨在探讨特定实验室结果异常和高血压与估计肾小球滤过率(eGFR)和白蛋白尿 CKD 分期框架的关系。

研究设计

全球联盟的横断面个体参与者水平分析。

研究人群和设置

17 个 CKD 队列和 38 个一般人群和高危队列。

研究选择标准

CKD 预后联盟中的队列,具有 eGFR 和白蛋白尿数据,以及血红蛋白、碳酸氢盐、磷、甲状旁腺激素、钾或钙的测量值,或高血压。

数据提取

数据于 2015 年 7 月至 2018 年 1 月之间获取和分析。

分析方法

我们使用线性回归模型研究 eGFR 和白蛋白尿与血红蛋白、碳酸氢盐、磷、甲状旁腺激素、钾和钙值之间的关联,以及使用 logistic 回归模型研究高血压和每种异常的分类定义之间的关联。使用随机效应荟萃分析对结果进行汇总。

结果

CKD 队列(n=254666 名参与者)中 27%为女性,10%为黑人,平均年龄为 69(SD,12)岁。一般人群/高危队列(n=1758334 名参与者)中 50%为女性,2%为黑人,平均年龄为 50(16)岁。较低的 eGFR 与所有实验室结果异常呈强分级关联(OR 范围为 3.27[95%CI,2.68-3.97]至 8.91[95%CI,7.22-10.99],比较 eGFR 为 15 至 29 与 eGFR 为 45 至 59mL/min/1.73m),而白蛋白尿与异常的关联则不明确或较弱(OR 范围为 0.77[95%CI,0.60-0.99]至 1.92[95%CI,1.65-2.24],比较尿白蛋白-肌酐比值>300 与<30mg/g)。

局限性

研究时代、医疗保健系统、典型饮食和实验室检测的差异。

结论

较低的 eGFR 与多种实验室结果异常的高几率强烈相关。对风险关联的了解可能有助于指导 CKD 异质患者的管理。

相似文献

1
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.估算肾小球滤过率和蛋白尿与同期实验室异常的关系:全球联盟的个体参与者数据荟萃分析。
Am J Kidney Dis. 2019 Feb;73(2):206-217. doi: 10.1053/j.ajkd.2018.08.013. Epub 2018 Oct 19.
2
Biological Variability of Estimated GFR and Albuminuria in CKD.估算肾小球滤过率和蛋白尿在慢性肾脏病中的生物学变异性。
Am J Kidney Dis. 2018 Oct;72(4):538-546. doi: 10.1053/j.ajkd.2018.04.023. Epub 2018 Jul 18.
3
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.非白蛋白尿性慢性肾脏病向终末期肾病进展的风险:CRIC(慢性肾功能不全队列)研究。
Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18.
4
Prevalence of chronic kidney disease defined by using CKD-EPI equation and albumin-to-creatinine ratio in the Korean adult population.使用CKD-EPI方程和白蛋白与肌酐比值定义的慢性肾脏病在韩国成年人群中的患病率。
Korean J Intern Med. 2016 Nov;31(6):1120-1130. doi: 10.3904/kjim.2015.193. Epub 2016 Mar 25.
5
A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury.估算肾小球滤过率、蛋白尿、年龄、种族和性别与急性肾损伤相关性的荟萃分析
Am J Kidney Dis. 2015 Oct;66(4):591-601. doi: 10.1053/j.ajkd.2015.02.337. Epub 2015 May 2.
6
Trends in Albuminuria and GFR Among Adolescents in the United States, 1988-2014.美国青少年白蛋白尿和肾小球滤过率的趋势,1988-2014 年。
Am J Kidney Dis. 2018 Nov;72(5):644-652. doi: 10.1053/j.ajkd.2018.04.021. Epub 2018 Jul 14.
7
A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury.估算肾小球滤过率、蛋白尿、糖尿病和高血压与急性肾损伤相关性的荟萃分析
Am J Kidney Dis. 2015 Oct;66(4):602-12. doi: 10.1053/j.ajkd.2015.02.338. Epub 2015 May 11.
8
Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.老年人肾功能作为心血管结局和死亡率的危险因素和预测因素。
Am J Kidney Dis. 2021 Mar;77(3):386-396.e1. doi: 10.1053/j.ajkd.2020.09.015. Epub 2020 Nov 14.
9
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.估算肾小球滤过率、白蛋白尿与不良结局:一项个体参与者数据的荟萃分析。
JAMA. 2023 Oct 3;330(13):1266-1277. doi: 10.1001/jama.2023.17002.
10
Comparison of associations of urine protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis.尿蛋白-肌酐比值与白蛋白-肌酐比值与 CKD 并发症相关性的比较:一项横断面分析。
Am J Kidney Dis. 2013 Dec;62(6):1102-8. doi: 10.1053/j.ajkd.2013.07.013. Epub 2013 Sep 14.

引用本文的文献

1
Pathophysiology and causes of hyperkalemia: unraveling causes beyond kidney dysfunction.高钾血症的病理生理学与病因:揭示肾功能不全以外的病因
Clin Exp Nephrol. 2025 Jun 11. doi: 10.1007/s10157-025-02711-x.
2
The ratio of chloride to bicarbonate is a predictor of advanced metabolic acidosis in CKD stages G4 and G5.氯与碳酸氢根的比值是慢性肾脏病G4和G5期严重代谢性酸中毒的一个预测指标。
Sci Rep. 2025 Jun 6;15(1):19958. doi: 10.1038/s41598-025-05633-6.
3
Druggability Studies of Benzene Sulfonamide Substituted Diarylamide (E3) as a Novel Diuretic.

本文引用的文献

1
Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). . 2017;7:1-59.勘误:肾脏疾病:改善全球预后(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)更新工作组。KDIGO 2017慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估、预防及治疗临床实践指南更新。. 2017;7:1-59。
Kidney Int Suppl (2011). 2017 Dec;7(3):e1. doi: 10.1016/j.kisu.2017.10.001. Epub 2017 Nov 17.
2
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.全球肾脏健康 2017 及以后:缩小照护、研究和政策差距的路线图。
Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.
3
新型利尿剂苯磺酰胺取代二芳基酰胺(E3)的成药特性研究
Biomedicines. 2025 Apr 18;13(4):992. doi: 10.3390/biomedicines13040992.
4
Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats.低氧诱导因子脯氨酰羟化酶抑制剂联合铁剂治疗大鼠肾性贫血的研究
BMC Nephrol. 2025 Mar 6;26(1):125. doi: 10.1186/s12882-025-04045-y.
5
Non-inferiority of sodium zirconium cyclosilicate versus potassium-restricted diet in achieving normokalaemia in patients with type 2 diabetes mellitus: protocol for a multicentre, open-label, randomised controlled, two-arm clinical trial (SILVERSTAR study).环硅酸锆钠与限钾饮食在2型糖尿病患者实现血钾正常方面的非劣效性:一项多中心、开放标签、随机对照、双臂临床试验的方案(SILVERSTAR研究)
BMJ Open. 2025 Mar 3;15(3):e089564. doi: 10.1136/bmjopen-2024-089564.
6
Association between atherosclerosis and the development of multi-organ pathologies.动脉粥样硬化与多器官病变发展之间的关联。
SAGE Open Med. 2024 Dec 23;12:20503121241310013. doi: 10.1177/20503121241310013. eCollection 2024.
7
Efficacy of probiotic, prebiotic, and synbiotics supplements in individuals with anemia: a systematic review and meta-analysis of randomized controlled trials.益生菌、益生元及合生元补充剂对贫血个体的疗效:一项随机对照试验的系统评价和荟萃分析
BMC Gastroenterol. 2024 Dec 23;24(1):472. doi: 10.1186/s12876-024-03562-8.
8
Predictive Value of Serum Hepcidin Levels for the Risk of Incident End-Stage Kidney Disease in Patients with Chronic Kidney Disease: The KNOW-CKD.血清铁调素水平对慢性肾脏病患者发生终末期肾病风险的预测价值:慢性肾脏病知晓研究(KNOW-CKD)
Kidney Dis (Basel). 2024 Oct 16;10(6):492-503. doi: 10.1159/000542057. eCollection 2024 Dec.
9
[What is confirmed in the treatment of metabolic acidosis in chronic kidney disease?].[慢性肾脏病代谢性酸中毒治疗中得到证实的是什么?]
Inn Med (Heidelb). 2024 Dec;65(12):1209-1215. doi: 10.1007/s00108-024-01806-z. Epub 2024 Nov 8.
10
Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia.地西司他:一种用于治疗慢性肾脏病所致贫血的新型脯氨酰羟化酶抑制剂。
Front Nephrol. 2024 Oct 22;4:1459425. doi: 10.3389/fneph.2024.1459425. eCollection 2024.
Assessment of Global Kidney Health Care Status.全球肾脏健康护理状况评估。
JAMA. 2017 May 9;317(18):1864-1881. doi: 10.1001/jama.2017.4046.
4
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.蛋白尿早期变化作为肾脏病进展的替代终点:一项个体患者荟萃分析。
Am J Kidney Dis. 2014 Jul;64(1):74-85. doi: 10.1053/j.ajkd.2014.02.020. Epub 2014 Apr 29.
5
The association of chronic kidney disease complications by albuminuria and glomerular filtration rate: a cross-sectional analysis.白蛋白尿和肾小球滤过率与慢性肾脏病并发症的关联:一项横断面分析。
Clin Nephrol. 2013 Jul;80(1):29-39. doi: 10.5414/cn107842.
6
Chronic kidney disease: global dimension and perspectives.慢性肾脏病:全球维度与展望。
Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.
7
Evolving importance of kidney disease: from subspecialty to global health burden.肾脏病的重要性不断演变:从亚专业到全球健康负担。
Lancet. 2013 Jul 13;382(9887):158-69. doi: 10.1016/S0140-6736(13)60439-0. Epub 2013 May 31.
8
Cohort profile: the chronic kidney disease prognosis consortium.队列简介:慢性肾脏病预后联盟
Int J Epidemiol. 2013 Dec;42(6):1660-8. doi: 10.1093/ije/dys173. Epub 2012 Dec 12.
9
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.比较 CKD-EPI 方程和 MDRD 研究方程用于估计肾小球滤过率的风险预测。
JAMA. 2012 May 9;307(18):1941-51. doi: 10.1001/jama.2012.3954.
10
Estimated GFR, albuminuria, and complications of chronic kidney disease.估算肾小球滤过率、蛋白尿和慢性肾脏病并发症。
J Am Soc Nephrol. 2011 Dec;22(12):2322-31. doi: 10.1681/ASN.2010111181. Epub 2011 Sep 30.